TY - JOUR
T1 - Computational approaches to support comparative analysis of multiparametric tests
T2 - Modelling versus Training
AU - OPTIMA Trial Management Group
AU - Bartlett, John M.S.
AU - Bayani, Jane
AU - Kornaga, Elizabeth N.
AU - Danaher, Patrick
AU - Crozier, Cheryl
AU - Piper, Tammy
AU - Yao, Cindy Q.
AU - Dunn, Janet A.
AU - Boutros, Paul C.
AU - Stein, Robert C.
AU - Cameron, David A.
AU - Campbell, Amy
AU - Canney, Peter
AU - Donovan, Jenny
AU - Dunn, Janet
AU - Earl, Helena
AU - Falzon, Mary
AU - Francis, Adele
AU - Hall, Peter
AU - Harmer, Victoria
AU - Higgins, Helen
AU - Hughes-Davies, Luke
AU - Hulme, Claire
AU - Macpherson, Iain
AU - Marshall, Andrea
AU - Makris, Andreas
AU - McCabe, Chris
AU - Morgan, Adrienne
AU - Pinder, Sarah
AU - Poole, Chris
AU - Rea, Daniel
AU - Rooshenas, Leila
AU - Stallard, Nigel
AU - Stein, Robert C.
PY - 2020/9/3
Y1 - 2020/9/3
N2 - Multiparametric assays for risk stratification are widely used in the management of breast cancer, with applications being developed for a number of other cancer settings. Recent data from multiple sources suggests that different tests may provide different risk estimates at the individual patient level. There is an increasing need for robust methods to support cost effective comparisons of test performance in multiple settings. The derivation of similar risk classifications using genes comprising the following multi-parametric tests Oncotype DX® (Genomic Health.), Prosigna™ (NanoString Technologies, Inc.), MammaPrint® (Agendia Inc.) was performed using different computational approaches. Results were compared to the actual test results. Two widely used approaches were applied, firstly computational “modelling” of test results using published algorithms and secondly a “training” approach which used reference results from the commercially supplied tests. We demonstrate the potential for errors to arise when using a “modelling” approach without reference to real world test results. Simultaneously we show that a “training” approach can provide a highly cost-effective solution to the development of real-world comparisons between different multigene signatures. Comparisons between existing multiparametric tests is challenging, and evidence on discordance between tests in risk stratification presents further dilemmas. We present an approach, modelled in breast cancer, which can provide health care providers and researchers with the potential to perform robust and meaningful comparisons between multigene tests in a cost-effective manner. We demonstrate that whilst viable estimates of gene signatures can be derived from modelling approaches, in our study using a training approach allowed a close approximation to true signature results.
AB - Multiparametric assays for risk stratification are widely used in the management of breast cancer, with applications being developed for a number of other cancer settings. Recent data from multiple sources suggests that different tests may provide different risk estimates at the individual patient level. There is an increasing need for robust methods to support cost effective comparisons of test performance in multiple settings. The derivation of similar risk classifications using genes comprising the following multi-parametric tests Oncotype DX® (Genomic Health.), Prosigna™ (NanoString Technologies, Inc.), MammaPrint® (Agendia Inc.) was performed using different computational approaches. Results were compared to the actual test results. Two widely used approaches were applied, firstly computational “modelling” of test results using published algorithms and secondly a “training” approach which used reference results from the commercially supplied tests. We demonstrate the potential for errors to arise when using a “modelling” approach without reference to real world test results. Simultaneously we show that a “training” approach can provide a highly cost-effective solution to the development of real-world comparisons between different multigene signatures. Comparisons between existing multiparametric tests is challenging, and evidence on discordance between tests in risk stratification presents further dilemmas. We present an approach, modelled in breast cancer, which can provide health care providers and researchers with the potential to perform robust and meaningful comparisons between multigene tests in a cost-effective manner. We demonstrate that whilst viable estimates of gene signatures can be derived from modelling approaches, in our study using a training approach allowed a close approximation to true signature results.
UR - http://www.scopus.com/inward/record.url?scp=85090320659&partnerID=8YFLogxK
U2 - 10.1371/journal.pone.0238593
DO - 10.1371/journal.pone.0238593
M3 - Article
C2 - 32881987
AN - SCOPUS:85090320659
SN - 1932-6203
VL - 15
JO - PLoS ONE
JF - PLoS ONE
IS - 9 September
M1 - e0238593
ER -